Redemplo® (plozasiran) injection

You are invited to attend an upcoming program hosted by Arrowhead Pharmaceuticals. This event will feature expert faculty discussing the data and insights on Redemplo® (plozasiran).

Redemplo® (plozasiran): A Treatment to Lower Triglycerides in Adults With Familial Chylomicronemia Syndrome (FCS)

INDICATION

REDEMPLO® (plozasiran) is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

See Important Safety Information below.



John Isaac, M.D.
Willowbrook Cardiovascular Associates

November 18, 2026
6:15 PM CT
Program ID: 207

Avenida Brazil Churrascaria Steakhouse
201 West Bay Area Boulevard
Webster, TX 77598
(281) 557-9999

Arrowhead representative

Cheryl Hildreth
childreth@arrowheadpharma.com

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

ADVERSE REACTIONS: Most common adverse reactions in REDEMPLO treated patients (incidence ≥10% of patients treated with REDEMPLO and > 5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction.

Please see full Prescribing Information for REDEMPLO at https://arrowheadpharma.com/en-us/redemplo/prescribing-information.pdf or scan the QR code.

Reference: Redemplo. Prescribing information. Arrowhead Pharmaceuticals, Inc.; 2025.

Redemplo is a registered trademark of Arrowhead Pharmaceuticals, Inc.
© 2026 Arrowhead Pharmaceuticals, Inc. All rights reserved. Not for reproduction or distribution.
MAT-0620-v2.0-05/2026

arrowhead pharmaceuticals